Form 4: IDEXX Laboratories Director Stuart Essig Reports Stock Transactions
SEC Form 4 Filing
Director Stuart Essig reports acquisition and disposal of IDEXX Laboratories stock and derivative securities.
Summary
- On May 6, 2025, Stuart Essig, a director of IDEXX Laboratories, reported transactions involving the company's stock.
- Essig acquired 262 shares of common stock through the vesting of restricted stock units.
- Essig disposed of 2,236 shares of common stock.
- Essig also acquired 600 non-qualified stock options with an exercise price of $486.61, exercisable from May 7, 2025, and expiring on May 6, 2035.
- Additionally, Essig acquired 257 deferred stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common practice and required by the SEC to ensure transparency and prevent insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 05/06/2025 | Date of common stock transaction and restricted stock unit vesting. |
| 05/07/2025 | Date non-qualified stock options become exercisable and deferred stock units vest. |
| 05/06/2035 | Expiration date of non-qualified stock options. |
| 05/08/2025 | Date of signature on the Form 4 filing. |
Keywords
IDEXX Laboratories, Stuart Essig, Form 4, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, Securities, IDXX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.